Pharma & Biotech

A curious divergence defines the current situation for Bionxt Solutions. The company continues to hit significant operational targets, yet its...

The investment case for Eli Lilly continues to strengthen, even after the pharmaceutical giant surpassed a $1 trillion market valuation....

Eli Lilly has cemented its leadership in the pharmaceutical industry by becoming the first company in the sector to surpass...

While Healwell AI has reported staggering financial growth, its stock performance tells a contradictory and alarming story. The company's latest...

AngioDynamics is demonstrating remarkable market momentum, driven by impressive quarterly results, favorable analyst coverage, and a significant regulatory development concerning...

CureVac is preparing to conclude its journey as an independent entity, but not before delivering a significant financial surprise. As...

The independent trading journey of Chinook Therapeutics shares has concluded. In a strategic move finalized in August 2023, the biotechnology...

Investors in French vaccine developer Valneva are facing a period of intense uncertainty. The company's latest financial report presents a...

While market sentiment remains divided, a significant move by a major investment firm suggests growing institutional confidence in gene-editing specialist...

Investors in Bionxt Solutions are grappling with a puzzling market dynamic where positive corporate developments appear disconnected from share price...